226 related articles for article (PubMed ID: 30353642)
1. CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL.
Chen Y; Peubez C; Smith V; Xiong S; Kocsis-Fodor G; Kennedy B; Wagner S; Balotis C; Jayne S; Dyer MJS; Macip S
J Cell Mol Med; 2019 Jan; 23(1):340-348. PubMed ID: 30353642
[TBL] [Abstract][Full Text] [Related]
2. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
Ishikawa C; Mori N
Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
4. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
[TBL] [Abstract][Full Text] [Related]
5. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
6. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
Endo T; Nishio M; Enzler T; Cottam HB; Fukuda T; James DF; Karin M; Kipps TJ
Blood; 2007 Jan; 109(2):703-10. PubMed ID: 16973958
[TBL] [Abstract][Full Text] [Related]
7. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
8. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG
Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411
[TBL] [Abstract][Full Text] [Related]
9. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.
Nishio M; Endo T; Tsukada N; Ohata J; Kitada S; Reed JC; Zvaifler NJ; Kipps TJ
Blood; 2005 Aug; 106(3):1012-20. PubMed ID: 15860672
[TBL] [Abstract][Full Text] [Related]
10. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.
Cols M; Barra CM; He B; Puga I; Xu W; Chiu A; Tam W; Knowles DM; Dillon SR; Leonard JP; Furman RR; Chen K; Cerutti A
J Immunol; 2012 Jun; 188(12):6071-83. PubMed ID: 22593611
[TBL] [Abstract][Full Text] [Related]
11. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
[TBL] [Abstract][Full Text] [Related]
12. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
13. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
Paiva C; Rowland TA; Sreekantham B; Godbersen C; Best SR; Kaur P; Loriaux MM; Spurgeon SEF; Danilova OV; Danilov AV
Haematologica; 2017 Nov; 102(11):1890-1900. PubMed ID: 28838991
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
[TBL] [Abstract][Full Text] [Related]
15. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.
Ferrer G; Bosch R; Hodgson K; Tejero R; Roué G; Colomer D; Montserrat E; Moreno C
Br J Haematol; 2014 Feb; 164(4):570-8. PubMed ID: 24245956
[TBL] [Abstract][Full Text] [Related]
16. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Han TT; Fan L; Li JY; Xu W
Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438
[TBL] [Abstract][Full Text] [Related]
17. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
19. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.
Kern C; Cornuel JF; Billard C; Tang R; Rouillard D; Stenou V; Defrance T; Ajchenbaum-Cymbalista F; Simonin PY; Feldblum S; Kolb JP
Blood; 2004 Jan; 103(2):679-88. PubMed ID: 14504101
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
